Rules of Conduct
Good Behavior Code in the Pharma market has been presented to the professional community.
The idea for the need of such a document belongs to Igor Artemiev, Head of the Federal Antimonopoly Service of Russia. During his presentation at an annual briefing of the European Business Association (EBA) in September, 2014, he suggested that the pharmaceutical community develop a document similar to the Code of Automobile Manufacturers, which showed itself to a good advantage.
The key objective of the Code of Good Conduct in the pharma market is to provide self-regulation of the pharma business in the territory of the Russian Federation and to create just, open and responsible rules of competitive interaction in the pharmaceutical industry. Such a document has been long awaited for, as our legislation does not regulate certain aspects of relations between pharmaceutical manufacturers and different categories of drug consumers. The code is a set of rules of acceptable conduct of stakeholders in the pharmaceutical market. Its scope extends to drug market participants. The code includes clauses on contractual obligations of manufacturers of drugs with buyers, on principles of coordination with distributors, commercial terms and conditions of deliveries to public clients, on consideration of disputes between the code participants and on many other aspects.
Chairman of EBA Committee on pharmaceutics and healthcare, General Director of Chiesi Pharmaceuticals Yuri Litvischenko remarked that the Code was developed in cooperation with pharmaceutical companies and FAS experts. Professional Associations were involved in its development.